Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A.

Sci Rep. 2017 Mar 10;7:44125. doi: 10.1038/srep44125.

2.

Genetic controls of DNA damage avoidance in response to acetaldehyde in fission yeast.

Noguchi C, Grothusen G, Anandarajan V, Martínez-Lage García M, Terlecky D, Corzo K, Tanaka K, Nakagawa H, Noguchi E.

Cell Cycle. 2017 Jan 2;16(1):45-58. doi: 10.1080/15384101.2016.1237326. Epub 2016 Sep 29.

3.

Targeted Antioxidant, Catalase-SKL, Reduces Beta-Amyloid Toxicity in the Rat Brain.

Nell HJ, Au JL, Giordano CR, Terlecky SR, Walton PA, Whitehead SN, Cechetto DF.

Brain Pathol. 2017 Jan;27(1):86-94. doi: 10.1111/bpa.12368. Epub 2016 Jun 13.

PMID:
26919450
4.

Peroxisome biogenesis in mammalian cells: The impact of genes and environment.

Farr RL, Lismont C, Terlecky SR, Fransen M.

Biochim Biophys Acta. 2016 May;1863(5):1049-60. doi: 10.1016/j.bbamcr.2015.08.011. Epub 2015 Aug 21. Review.

5.

Catalase therapy corrects oxidative stress-induced pathophysiology in incipient diabetic retinopathy.

Giordano CR, Roberts R, Krentz KA, Bissig D, Talreja D, Kumar A, Terlecky SR, Berkowitz BA.

Invest Ophthalmol Vis Sci. 2015 May;56(5):3095-102. doi: 10.1167/iovs.14-16194.

6.

Amyloid-beta neuroprotection mediated by a targeted antioxidant.

Giordano CR, Terlecky LJ, Bollig-Fischer A, Walton PA, Terlecky SR.

Sci Rep. 2014 May 15;4:4983. doi: 10.1038/srep04983.

7.

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.

Giordano CR, Mueller KL, Terlecky LJ, Krentz KA, Bollig-Fischer A, Terlecky SR, Boerner JL.

Exp Cell Res. 2012 Oct 1;318(16):2014-21. doi: 10.1016/j.yexcr.2012.06.001. Epub 2012 Jun 8.

8.

Peroxisomes, oxidative stress, and inflammation.

Terlecky SR, Terlecky LJ, Giordano CR.

World J Biol Chem. 2012 May 26;3(5):93-7. doi: 10.4331/wjbc.v3.i5.93.

9.

Peroxisomes, cell senescence, and rates of aging.

Giordano CR, Terlecky SR.

Biochim Biophys Acta. 2012 Sep;1822(9):1358-62. doi: 10.1016/j.bbadis.2012.03.013. Epub 2012 Mar 29. Review.

10.

Intraperoxisomal redox balance in mammalian cells: oxidative stress and interorganellar cross-talk.

Ivashchenko O, Van Veldhoven PP, Brees C, Ho YS, Terlecky SR, Fransen M.

Mol Biol Cell. 2011 May;22(9):1440-51. doi: 10.1091/mbc.E10-11-0919. Epub 2011 Mar 3.

11.

Peroxisome metabolism and cellular aging.

Titorenko VI, Terlecky SR.

Traffic. 2011 Mar;12(3):252-9. doi: 10.1111/j.1600-0854.2010.01144.x. Epub 2010 Dec 6. Review.

12.

Targeted intracellular catalase delivery protects neonatal rat myocytes from hypoxia-reoxygenation and ischemia-reperfusion injury.

Undyala V, Terlecky SR, Vander Heide RS.

Cardiovasc Pathol. 2011 Sep-Oct;20(5):272-80. doi: 10.1016/j.carpath.2010.06.011. Epub 2010 Aug 12.

13.

Diabetes increases susceptibility of primary cultures of rat proximal tubular cells to chemically induced injury.

Zhong Q, Terlecky SR, Lash LH.

Toxicol Appl Pharmacol. 2009 Nov 15;241(1):1-13. doi: 10.1016/j.taap.2009.08.007. Epub 2009 Aug 12.

PMID:
19682476
14.

A role for hydrogen peroxide in the pro-apoptotic effects of photodynamic therapy.

Price M, Terlecky SR, Kessel D.

Photochem Photobiol. 2009 Nov-Dec;85(6):1491-6. doi: 10.1111/j.1751-1097.2009.00589.x.

15.

Progeric effects of catalase inactivation in human cells.

Koepke JI, Wood CS, Terlecky LJ, Walton PA, Terlecky SR.

Toxicol Appl Pharmacol. 2008 Oct 1;232(1):99-108. doi: 10.1016/j.taap.2008.06.004. Epub 2008 Jun 24.

PMID:
18634817
16.

Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease.

Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd Savoy L, Terlecky SR.

J Invest Dermatol. 2008 Nov;128(11):2606-14. doi: 10.1038/jid.2008.122. Epub 2008 May 8. Erratum in: J Invest Dermatol. 2009 Jul;129(7):1838. Boyd, Savoy L [corrected to Boyd Savoy, L].

17.

In vitro analysis of peroxisomal protein import.

Terlecky SR.

Curr Protoc Cell Biol. 2002 May;Chapter 11:Unit 11.15. doi: 10.1002/0471143030.cb1115s14.

PMID:
18228397
18.

Restoration of peroxisomal catalase import in a model of human cellular aging.

Koepke JI, Nakrieko KA, Wood CS, Boucher KK, Terlecky LJ, Walton PA, Terlecky SR.

Traffic. 2007 Nov;8(11):1590-600. Epub 2007 Sep 6.

19.

Drug delivery to peroxisomes: employing unique trafficking mechanisms to target protein therapeutics.

Terlecky SR, Koepke JI.

Adv Drug Deliv Rev. 2007 Aug 10;59(8):739-47. Epub 2007 Jun 28. Review.

PMID:
17659806
20.

Peroxisomes and aging.

Terlecky SR, Koepke JI, Walton PA.

Biochim Biophys Acta. 2006 Dec;1763(12):1749-54. Epub 2006 Aug 23. Review.

21.

Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies.

Wood CS, Koepke JI, Teng H, Boucher KK, Katz S, Chang P, Terlecky LJ, Papanayotou I, Walton PA, Terlecky SR.

Traffic. 2006 Jan;7(1):97-107.

22.

Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.

Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC.

J Virol. 2004 Mar;78(6):3123-32.

23.

Protein structure and import into the peroxisomal matrix.

Brocard CB, Jedeszko C, Song HC, Terlecky SR, Walton PA.

Traffic. 2003 Feb;4(2):74-82.

24.

Peroxisome senescence in human fibroblasts.

Legakis JE, Koepke JI, Jedeszko C, Barlaskar F, Terlecky LJ, Edwards HJ, Walton PA, Terlecky SR.

Mol Biol Cell. 2002 Dec;13(12):4243-55.

25.

PTS2 protein import into mammalian peroxisomes.

Legakis JE, Terlecky SR.

Traffic. 2001 Apr;2(4):252-60.

26.

How peroxisomes arise.

Terlecky SR, Fransen M.

Traffic. 2000 Jun;1(6):465-73. Review.

27.

Quantitative analysis of peroxisomal protein import in vitro.

Terlecky SR, Legakis JE, Hueni SE, Subramani S.

Exp Cell Res. 2001 Feb 1;263(1):98-106.

PMID:
11161709
28.

Redundant and distinct functions for dynamin-1 and dynamin-2 isoforms.

Altschuler Y, Barbas SM, Terlecky LJ, Tang K, Hardy S, Mostov KE, Schmid SL.

J Cell Biol. 1998 Dec 28;143(7):1871-81.

29.

Use of Pichia pastoris as a model eukaryotic system. Peroxisome biogenesis.

Faber KN, Elgersma Y, Heyman JA, Koller A, Lüers GH, Nuttley WM, Terlecky SR, Wenzel TJ, Subramani S.

Methods Mol Biol. 1998;103:121-47. No abstract available.

PMID:
9680638
30.

Identification of a human PTS1 receptor docking protein directly required for peroxisomal protein import.

Fransen M, Terlecky SR, Subramani S.

Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8087-92.

31.

An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation.

Agarraberes FA, Terlecky SR, Dice JF.

J Cell Biol. 1997 May 19;137(4):825-34.

32.

Signals, receptors, and cytosolic factors involved in peroxisomal protein import.

Terlecky SR, Wiemer EA, Nuttley WM, Walton PA, Subramani S.

Ann N Y Acad Sci. 1996 Dec 27;804:11-20. Review.

PMID:
8993532
33.

The cytosolic and membrane components required for peroxisomal protein import.

Terlecky SR, Nuttley WM, Subramani S.

Experientia. 1996 Dec 15;52(12):1050-4. Review.

PMID:
8988245
34.

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo.

Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P.

Nature. 1996 Jul 18;382(6588):275-8.

PMID:
8717046
35.

Regulation of receptor-mediated endocytosis by Rho and Rac.

Lamaze C, Chuang TH, Terlecky LJ, Bokoch GM, Schmid SL.

Nature. 1996 Jul 11;382(6587):177-9.

PMID:
8700210
36.

Activation of a selective pathway of lysosomal proteolysis in rat liver by prolonged starvation.

Cuervo AM, Knecht E, Terlecky SR, Dice JF.

Am J Physiol. 1995 Nov;269(5 Pt 1):C1200-8.

PMID:
7491910
37.

The Pichia pastoris peroxisomal protein PAS8p is the receptor for the C-terminal tripeptide peroxisomal targeting signal.

Terlecky SR, Nuttley WM, McCollum D, Sock E, Subramani S.

EMBO J. 1995 Aug 1;14(15):3627-34.

38.

Dynamin GTPase is stimulated by crosslinking through the C-terminal proline-rich domain.

Warnock DE, Terlecky LJ, Schmid SL.

EMBO J. 1995 Apr 3;14(7):1322-8.

39.

Characterization of the yeast and human receptors for the carboxy-terminal tripeptide peroxisomal targeting signal.

Wiemer EA, Terlecky SR, Nuttley WM, Subramani S.

Cold Spring Harb Symp Quant Biol. 1995;60:637-48. No abstract available.

PMID:
8824437
40.

Hsp70s and lysosomal proteolysis.

Terlecky SR.

Experientia. 1994 Nov 30;50(11-12):1021-5. Review.

PMID:
7988660
41.
42.

Polypeptide import and degradation by isolated lysosomes.

Terlecky SR, Dice JF.

J Biol Chem. 1993 Nov 5;268(31):23490-5.

43.
44.

A pathway of lysosomal proteolysis mediated by the 73-kilodalton heat shock cognate protein.

Terlecky SR, Olson TS, Dice JF.

Acta Biol Hung. 1991;42(1-3):39-47. Review.

PMID:
1844319
45.

Targeting specific proteins for lysosomal proteolysis.

Olson TS, Terlecky SR, Dice JF.

Biomed Biochim Acta. 1991;50(4-6):393-7.

PMID:
1801703
46.

A selective pathway for degradation of cytosolic proteins by lysosomes.

Dice JF, Terlecky SR, Chiang HL, Olson TS, Isenman LD, Short-Russell SR, Freundlieb S, Terlecky LJ.

Semin Cell Biol. 1990 Dec;1(6):449-55. Review.

PMID:
2103896
47.

Targeting of cytosolic proteins to lysosomes for degradation.

Dice JF, Terlecky SR.

Crit Rev Ther Drug Carrier Syst. 1990;7(3):211-33. Review.

PMID:
2073687
48.

A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins.

Chiang HL, Terlecky SR, Plant CP, Dice JF.

Science. 1989 Oct 20;246(4928):382-5.

PMID:
2799391
49.
50.

Preparation of pyrogen-free inulin for measurement of glomerular filtration rate.

Simenhoff ML, Wesson LG Jr, Terlecky JS.

Clin Chim Acta. 1970 Feb;27(2):367-8. No abstract available.

PMID:
5417240

Supplemental Content

Support Center